Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41591-021-01294-w http://scihub22266oqcxt.onion/10.1038/s41591-021-01294-w 33664494!8058618!33664494     free     free     free Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nat+Med 2021 ; 27 (4): 717-726 Nephropedia Template TP {{tp|p=33664494|t=2021. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies |pdf=|usr=}}{{33664494}} gab.com Text Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies JO: Nat Med http://www.kidney.de/pget.php?&tw=1&pmid=33664494 #FOAvip Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the global COVID-19 pandemic. Rapidly spreading SARS-CoV-2 variants may jeopardize newly introduced antibody and vaccine countermeasures. Here, using monoclonal antibodies (mAbs), animal immune sera, human convalescent sera and human sera from recipients of the BNT162b2 mRNA vaccine, we report the impact on antibody neutralization of a panel of authentic SARS-CoV-2 variants including a B.1.1.7 isolate, chimeric strains with South African or Brazilian spike genes and isogenic recombinant viral variants. Many highly neutralizing mAbs engaging the receptor-binding domain or N-terminal domain and most convalescent sera and mRNA vaccine-induced immune sera showed reduced inhibitory activity against viruses containing an E484K spike mutation. As antibodies binding to spike receptor-binding domain and N-terminal domain demonstrate diminished neutralization potency in vitro against some emerging variants, updated mAb cocktails targeting highly conserved regions, enhancement of mAb potency or adjustments to the spike sequences of vaccines may be needed to prevent loss of protection in vivo. Twit Text FOAVip Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies ????Nat Med http://www.kidney.de/pget.php?&tw=1&pmid=33664494 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33664494 #FOAvip English Wikipedia <ref>{{Cite pmid|33664494}}</ref> Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies #MMPMID33664494 Chen RE; Zhang X; Case JB; Winkler ES; Liu Y; VanBlargan LA; Liu J; Errico JM; Xie X; Suryadevara N; Gilchuk P; Zost SJ; Tahan S; Droit L; Turner JS; Kim W; Schmitz AJ; Thapa M; Wang D; Boon ACM; Presti RM; O'Halloran JA; Kim AHJ; Deepak P; Pinto D; Fremont DH; Crowe JE Jr; Corti D; Virgin HW; Ellebedy AH; Shi PY; Diamond MS Nat Med 2021[Apr]; 27 (4): 717-726 PMID33664494show ga Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the global COVID-19 pandemic. Rapidly spreading SARS-CoV-2 variants may jeopardize newly introduced antibody and vaccine countermeasures. Here, using monoclonal antibodies (mAbs), animal immune sera, human convalescent sera and human sera from recipients of the BNT162b2 mRNA vaccine, we report the impact on antibody neutralization of a panel of authentic SARS-CoV-2 variants including a B.1.1.7 isolate, chimeric strains with South African or Brazilian spike genes and isogenic recombinant viral variants. Many highly neutralizing mAbs engaging the receptor-binding domain or N-terminal domain and most convalescent sera and mRNA vaccine-induced immune sera showed reduced inhibitory activity against viruses containing an E484K spike mutation. As antibodies binding to spike receptor-binding domain and N-terminal domain demonstrate diminished neutralization potency in vitro against some emerging variants, updated mAb cocktails targeting highly conserved regions, enhancement of mAb potency or adjustments to the spike sequences of vaccines may be needed to prevent loss of protection in vivo. |Animals[MESH] |Antibodies, Monoclonal/*immunology[MESH] |Antibodies, Neutralizing/*immunology[MESH] |Antibodies, Viral/*immunology[MESH] |BNT162 Vaccine[MESH] |COVID-19 Vaccines/immunology[MESH] |COVID-19/prevention & control[MESH] |Chlorocebus aethiops[MESH] |Cricetinae[MESH] |Humans[MESH] |Mice[MESH] |Mutation[MESH] |Neutralization Tests[MESH] |SARS-CoV-2/*immunology[MESH] |Spike Glycoprotein, Coronavirus/chemistry/genetics/immunology[MESH]Resistance of SARS-CoV-2 variants to neutralization by monoclonal and (epmc).pdf DeepDyve Pubget Overpricing